EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

Iterum Therapeutics has announced the FDA has approved ORLYNVAH (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs)

In a recent study presented at the 25th Annual Fall Scientific Meeting of SMSNA, similar diagnosing success was reported between self-diagnosis and diagnosis from a health care provider for vaginismus.

In a recent study, women with urinary incontinence were more likely to experience postpartum depression at both under and over 6 months after delivery.

The advisory committee meeting will discuss the potential approval of oral sulopenem etzadroxil/probenecid tablets for treating urinary tract infections in women aged 18 years and older.